The Goldman Sachs Group, Inc. 13D and 13G filings for Akero Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-07 4:31 pm Sale |
2022-12-30 | 13G | Akero Therapeutics, Inc. AKRO |
GOLDMAN SACHS GROUP INC GS |
474,564 1.000% |
-1,301,628 (-73.28%) |
Filing |
| 2022-02-08 4:19 pm Purchase |
2021-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
GOLDMAN SACHS GROUP INC GS |
1,776,192 5.100% |
1,776,192 (New Position) |
Filing |